<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937453</url>
  </required_header>
  <id_info>
    <org_study_id>18-01</org_study_id>
    <nct_id>NCT03937453</nct_id>
  </id_info>
  <brief_title>A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus</brief_title>
  <official_title>A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuvance Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nuvance Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to explore the relationship between new-onset diabetes&#xD;
      mellitus and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and&#xD;
      Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage&#xD;
      pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample&#xD;
      at specific intervals for the creation of a bio-bank necessary for the development of a blood&#xD;
      based screening test for pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals between 50-80 years of age who have developed diabetes mellitus within the&#xD;
      preceding year will be recruited through the offices of primary care physicians and&#xD;
      endocrinologists. Those meeting initial criteria will meet with a research nurse and will&#xD;
      undergo a secondary screen to determine eligibility. Individuals enrolled in the study will&#xD;
      undergo a five-minute psychological survey and donation of a blood sample for bio-bank&#xD;
      analysis every 6 months for 3 years. MRI will be performed annually for 2 years (3 in total).&#xD;
      Any abnormalities on MRI will be reviewed by a multi-disciplinary tumor board and discussed&#xD;
      with the participant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Anticipated">January 19, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Early Stage Pancreatic Cancer or Precursor Lesions</measure>
    <time_frame>Through study completion, up to 3 years</time_frame>
    <description>Determine incidence of pancreatic cancer or precursor lesions within a population of new-onset diabetes mellitus individuals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Risk of Pancreatic Cancer Among Individuals with New-Onset Diabetes</measure>
    <time_frame>Through study completion, up to 3 years</time_frame>
    <description>Assess utility of MRI as a screening tool for pancreatic cancer and ascertain relative risk of pancreatic cancer in study population of individuals with new-onset diabetes compared to a normal population of the same age</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>New-Onset Diabetes Mellitus</arm_group_label>
    <description>Diabetes Mellitus diagnosed within the past 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI/MRCP</intervention_name>
    <description>An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually</description>
    <arm_group_label>New-Onset Diabetes Mellitus</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50-80 years of age. New-onset diabetes mellitus (diagnosed with within the preceding 12&#xD;
        months)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 50-80 years.&#xD;
&#xD;
          -  DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of&#xD;
             prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c&#xD;
             ≥ 6.5% OR&#xD;
&#xD;
          -  DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record&#xD;
             of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR&#xD;
&#xD;
          -  Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months&#xD;
             characterized by a change in the HbA1c of ≥ 0.5% OR&#xD;
&#xD;
          -  DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or&#xD;
             Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%.&#xD;
&#xD;
          -  ECOG Performance Status of 0-1.&#xD;
&#xD;
          -  No known contraindications to MRI examination or gadolinium contrast.&#xD;
&#xD;
          -  Willing to undergo MRI and screening for metal implants or metal injury.&#xD;
&#xD;
          -  Recent BUN and Cr&#xD;
&#xD;
          -  Estimated GFR (eGFR) must be greater than 40 mL/min.&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
          -  Willing to return to study site for all study assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of pancreatic cancer.&#xD;
&#xD;
          -  Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the&#xD;
             past 5 years.&#xD;
&#xD;
          -  Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the&#xD;
             disease free interval is at least 5 years).&#xD;
&#xD;
          -  Hereditary pancreatitis.&#xD;
&#xD;
          -  eGFR &lt; 40 mL/min.&#xD;
&#xD;
          -  Contraindication to MRI examination or gadolinium contrast.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Co-morbid illnesses or other concurrent disease which, in the judgment of the&#xD;
             clinicians obtaining informed consent, would make the participant inappropriate for&#xD;
             entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Frank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuvance Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammy Lo, APRN</last_name>
    <phone>203-822-3551</phone>
    <email>Tammy.Lo@wchn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pramila Krumholtz, RN</last_name>
    <phone>203-739-7997</phone>
    <email>Pramila.Krumholtz@wchn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Farrell, MD</last_name>
      <email>James.J.Farrell@yale.edu</email>
    </contact>
    <investigator>
      <last_name>James Farrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Network</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Lo, APRN</last_name>
      <phone>203-822-3551</phone>
      <email>Tammy.Lo@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Richard Frank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.westernconnecticuthealthnetwork.org/departments/western-connecticut-health-network-research-and-innovation/office-of-clinical-trials/pancreatic-cancer-screening-study</url>
    <description>More information regarding the Pancreatic Cancer Screening Study may be found here</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nuvance Health</investigator_affiliation>
    <investigator_full_name>Richard Frank</investigator_full_name>
    <investigator_title>Director of Cancer Research</investigator_title>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Cancer</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>MRI</keyword>
  <keyword>Early Detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant data for all primary and secondary outcome measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed on an individual basis post submission. Requestors may be required to sign a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

